Company News-Gan & Lee

中文站

Careers | Investors | Patients and HCPS | Contact us

Careers Investors Patients and HCPS Contact us

Search

# Popular search #

Diabetes Oncology Medical Devices

Company News

Company News Exhibitions Activities

All news 2024 2023 2022 2021 2018

Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)
Gan & Lee 2024-09-14
Gan & Lee Pharmaceuticals to Present Positive Data from Two Clinical Studies of GZR4, a Once-weekly Insulin, at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)
Gan & Lee 2024-08-30
Gan & Lee’s Insulin Glargine U300 Clinical Research Findings Published in Frontiers in Endocrinology
Gan & Lee 2024-08-22
Gan & Lee Teams Up with Algerian Pharmaceutical Company to Pioneer New Horizons in African Market
Gan & Lee 2024-08-08
Gan & Lee Pharmaceuticals’ Bi-weekly（twice a month） GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial
Gan & Lee 2024-07-22
Gan & Lee Pharmaceuticals Successfully Shines at the American Diabetes Association's 84th Scientific Sessions
Gan & Lee 2024-07-11

< 1 2 3 4 5 6 7 8 ... 12 13 >

Our websites

Gangan Technology

You are now leaving the Gan & Lee website.

The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.

Continue Back

Search

Subscribe